Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib in germline BRCA or PALB2 mutated metastatic pancreatic cancer (phase 3)
CTR20200594Phase 3Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC), breast cancer and cancer comparing Fluzoparib with Placebo (2 arms). Primary endpoint: Progression-free survival (PFS) by BICR per RECIST v1.1. Started May 2020; status: terminated.
02
Drugs
fluzoparib
03
Conditions
pancreatic adenocarcinoma (PDAC)breast cancercancer
Beyond the preview
Go deeper on CTR20200594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200594.